window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : August 31, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Opella

  • Biotech & Pharma Business,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    Opella invests $70m in Mexico to expand Enterogermina production

    Slug:opella-mexico-enterogermina-investment Opella has invested $70 million in a new Enterogermina [...]

    July 23, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics

    Japan approves over-the-counter Cialis as Opella expands access to ED treatment

    Opella has received approval to make Cialis available without a [...]

    June 10, 2026
  • Biotech & Pharma Business,Pharmaceuticals and therapeutics

    Opella appoints former Reckitt executive Gonzalo Balcazar to lead Europe and Latin America

    Opella has appointed Gonzalo Balcazar as president of Europe and [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • MRI study suggests some prostate cancer biopsies could eventually be avoided
    Categories: Clinical & Regulatory, Medical devices, Research & Development, Therapeutic Areas
  • START and Allegheny Health Network to expand access to early-phase cancer trials
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Polaryx advances Phase 2 trial of PLX-200 in four rare diseases
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top